Ileal Interposition is a metabolic surgery procedure, used to treat overweight diabetic patients through surgical means. First presented by the Brazilian surgeon Aureo De Paula in 1999, this technique is applied by placing ileum, which is the distal part of the small intestine, either between stomach and the proximal part of the small intestine or by placing the ileum to the proximal part of the small intestine without touching the natural connections of the stomach.
There are two different versions of the operation. Sleeve gastrectomy procedure is standard for both of the versions.[citation needed]
Diverted (Duodeno-ileal interposition)
In addition to sleeve gastrectomy procedure, the connection between the stomach and the duodenum is closed off from the level of the second segment of the duodenum. While preserving the last 30cm part of the small intestine, a 170cm segment of ileum is prepared and connected to the first segment of the duodenum, which is at the end of the stomach. The other end of the ileum segment is connected to the proximal part of the small intestine. Thus, distal part of the small intestine is ‘’interposed’’ between proximal part of the small intestine and the stomach. Since duodenum and the proximal part of the small intestine is disabled, a partial bypass is in question. Patients who undergo this operation achieve better weight and blood sugar control, but face anemia (iron deficiency) risk because of the bypass procedure.[citation needed]
Non-Diverted (Jejuno-ileal interposition)
In addition to sleeve gastrectomy procedure, a 200 cm segment of ileum is prepared while preserving the last 30 cm part of the small intestine and then ‘’interposed’’ to the proximal part of the small intestine. Thanks to this, food continue to pass throughout the entire small intestine. No malabsorption is in question in this technique, and the food is absorbed by the duodenum as well. Since negative hormones secreted from the duodenum are quite effective in the surgical treatment of diabetes, this operation offers effective weight control, but has limited effect on blood sugar control.
Medical uses
Type 2 diabetic patients who cannot achieve blood sugar control despite appropriate treatment or suffering from organ damage should consider this operation. This is not a standard treatment for patients with low body mass index, and should only be performed in accordance with certain clinic protocols.[citation needed]
Physiology
Increase of GLP-1 levels because of early food contact with ileum mucosa, which in turn regulates early phase insulin secretion (jejuno ileal nutrient sensing)
Regulation of late term glucose dependent (20–120 minutes) plasma insulin response because of GIP effect (duodenal exclusion)
Two important advantages and one disadvantage about Ileal Transposition (Interposition) have been reported. First of the advantages is that it can be performed on patients with a broad range of BMI (Body Mass Index), and the other one is that with the exception of patients who already need iron, B12 vitamin and D vitamin supplement prior to the surgery, the operation does not necessitate any additional vitamin supplement. Its disadvantage is that the operation technically quite challenging because it consists of numerous stages and therefore require serious training and technical expertise.[citation needed]
Costs
Longer operation times than other procedures (3–3.5 hours), the need of technologically more advanced equipment and longer hospitalization cause higher costs than other commonly used, simpler procedures with limited effectiveness. The reported costs change between US$15,000–25,000.
↑Celik A, Ugale S, Ofluoglu H, Vural E, Cagiltay E, Cat H, Asci M, Celik BO (November 2015). "Metabolic Outcomes of Laparoscopic Diverted Sleeve Gastrectomy with Ileal Transposition (DSIT) in Obese Type 2 Diabetic Patients". Obes Surg. 25 (11): 2018–22. doi:10.1007/s11695-015-1671-1. PMID25893650.
DePaula AL, Macedo AL, Mota BR, Schraibman V (June 2009). "Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21-29". Surg Endosc. 23 (6): 1313–20. doi:10.1007/s00464-008-0156-x. PMID18830750.
DePaula AL, Stival AR, DePaula CC, Halpern A, Vêncio S (August 2010). "Impact on dyslipidemia of the laparoscopic ileal interposition associated to sleeve gastrectomy in type 2 diabetic patients". J Gastrointest Surg. 14 (8): 1319–25. doi:10.1007/s11605-010-1252-5. PMID20556664.
DePaula AL, Stival A, Halpern A, Vencio S (January 2011). "Thirty-day morbidity and mortality of the laparoscopic ileal interposition associated with sleeve gastrectomy for the treatment of type 2 diabetic patients with BMI <35: an analysis of 454 consecutive patients". World J Surg. 35 (1): 102–8. doi:10.1007/s00268-010-0799-3. PMID21052999.
DePaula AL, Stival AR, Halpern A, Vencio S (May 2011). "Surgical treatment of morbid obesity: mid-term outcomes of the laparoscopic ileal interposition associated to a sleeve gastrectomy in 120 patients". Obes Surg. 21 (5): 668–75. doi:10.1007/s11695-010-0232-x. PMID20652440.
De Paula AL, Stival AR, Halpern A, DePaula CC, Mari A, Muscelli E, Vencio S, Ferrannini E (August 2011). "Improvement in insulin sensitivity and β-cell function following ileal interposition with sleeve gastrectomy in type 2 diabetic patients: potential mechanisms". J Gastrointest Surg. 15 (8): 1344–53. doi:10.1007/s11605-011-1550-6. PMID21557013.
DePaula AL, Stival AR, DePaula CC, Halpern A, Vencio S (May 2012). "Surgical treatment of type 2 diabetes in patients with BMI below 35: mid-term outcomes of the laparoscopic ileal interposition associated with a sleeve gastrectomy in 202 consecutive cases". J Gastrointest Surg. 16 (5): 967–76. doi:10.1007/s11605-011-1807-0. PMID22350720.
Foschi DA, Rizzi A, Tubazio I, Conti L, Vago T, Bevilacqua M, Magni A, Del Puppo M (2015). "Duodenal diverted sleeve gastrectomy with ileal interposition does not cause biliary salt malabsorption". Surg Obes Relat Dis. 11 (2): 372–6. doi:10.1016/j.soard.2014.10.025. PMID25820074.
Kota SK, Ugale S, Gupta N, Modi KD (2012). "Laparoscopic ileal interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes". Diabetes Metab Syndr. 6 (3): 125–31. doi:10.1016/j.dsx.2012.09.014. PMID23158974.
Kumar KV, Ugale S, Gupta N, Naik V, Kumar P, Bhaskar P, Modi KD (December 2009). "Ileal interposition with sleeve gastrectomy for control of type 2 diabetes". Diabetes Technol Ther. 11 (12): 785–9. doi:10.1089/dia.2009.0070. PMID20001679.
Lakdawala M, Bhasker A (July 2010). "Report: Asian Consensus Meeting on Metabolic Surgery. Recommendations for the use of Bariatric and Gastrointestinal Metabolic Surgery for Treatment of Obesity and Type II Diabetes Mellitus in the Asian Population: August 9th and 10th, 2008, Trivandrum, India". Obes Surg. 20 (7): 929–36. doi:10.1007/s11695-010-0162-7. PMID20422309.
Tinoco A, El-Kadre L, Aquiar L, Tinoco R, Savassi-Rocha P (October 2011). "Short-term and mid-term control of type 2 diabetes mellitus by laparoscopic sleeve gastrectomy with ileal interposition". World J Surg. 35 (10): 2238–44. doi:10.1007/s00268-011-1188-2. PMID21744166.
Vencio S, Stival A, Halpern A, Depaula CC, DePaula AL (2011). "Early mechanisms of glucose improvement following laparoscopic ileal interposition associated with a sleeve gastrectomy evaluated by the euglycemic hyperinsulinemic clamp in type 2 diabetic patients with BMI below 35". Dig Surg. 28 (4): 293–8. doi:10.1159/000330272. PMID21894016.